Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis by Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K

Get full text

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. by Liedgens, H, Hertel, N, Gabriel, A, Nuijten, M, Dakin, H, Mitchell, S, Nautrup, B

Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe by Verleger K, Penrod JR, Manley Daumont M, Solem C, Luo L, Macahilig C, Hertel N

Get full text

Cost-effectiveness analysis of the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for post-herpetic neuralgia in Germany by Liedgens, H, Hertel, N, Gabriel, A, Nuijten, M, Dakin, H, Spoehrer, U, Poulsen Nautrup, B

Costutility analysis evaluating the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for postherpetic neuralgia in Germany by Liedgens, H, Hertel, N, Gabriel, A, Nuijten, M, Dakin, H, Sphrer, U, Poulsen Nautrup, B